Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
FRANKFURT (AFX) - Bayer AG's Bayer Schering Pharma business said the US Food and Drug Administration has approved a new indication for the company's oral contraception drug YAZ to treat moderate acne in women using oral contraceptive for birth control.
The company said the approval makes YAZ the only contraceptive ever approved by the FDA for three distinct indications.
"We are delighted to have received approval for YAZ in this third indication. We are convinced that through its unique features, YAZ will further strengthen our worldwide leading market position in the field of female contraception," said Phil Smits, head of the company's Women's Healthcare business unit.
YAZ received FDA approval as an oral contraceptive in March 2006 and as a treatment for premenstrual dysphoric disorder (PMDD) in October 2006. krysia.diver@afxnews.com kd/rar COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Copyright 2007 AFX News Limited. All Rights Reserved.
